Pharmac Notification: Decision to change funded brand of fulvestrant injection
- admin82291
- 6 days ago
- 1 min read
From 1 December 2025, Pharmac will be changing the funded brand of fulvestrant injection (50 mg per ml, 5 ml prefilled syringe), used to treat certain types of breast cancer.
The funded brand will change from Faslodex (AstraZeneca) to Fulvestrant EVER Pharma (InterPharma).
Fulvestrant EVER Pharma will be listed from 1 December 2025.
Faslodex will be delisted on 1 May 2026.
Fulvestrant EVER Pharma will be awarded Principal Supply Status from 1 May 2026 to 30 June 2028.
The new brand, Fulvestrant EVER Pharma, is approved and widely used in Australia. It is Medsafe approved and meets internationally agreed standards for safety, quality, and efficacy.
More information about this change is available here
Ngā mihi,
Pharmac | Te Pātaka Whaioranga | P: 0800 660 050 | www.pharmac.govt.nz
